300 related articles for article (PubMed ID: 31530019)
1. Antiresorptive drug-related changes of the mandibular bone densitiy in medication-related osteonecrosis of the jaw patients.
Heim N; Götz W; Kramer FJ; Faron A
Dentomaxillofac Radiol; 2019 Dec; 48(8):20190132. PubMed ID: 31530019
[TBL] [Abstract][Full Text] [Related]
2. Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis.
Schoenhof R; Munz A; Yuan A; ElAyouti A; Boesmueller H; Blumenstock G; Reinert S; Hoefert S
J Craniomaxillofac Surg; 2021 Jun; 49(6):508-517. PubMed ID: 33707134
[TBL] [Abstract][Full Text] [Related]
3. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
4. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
5. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
6. Sclerotic bone: a sign of bone reaction in patients with medication related osteonecrosis of the jaw.
Obermeier KT; Dewenter I; Malenova Y; Fliefel R; Kaeppler G; Otto S
Sci Rep; 2024 Apr; 14(1):7914. PubMed ID: 38575664
[TBL] [Abstract][Full Text] [Related]
7. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
8. Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature.
Chehal H; Nikitakis NG; Islam MN; Goodchild JH; Mordini L; Bhattacharyya I
Gen Dent; 2019; 67(1):42-46. PubMed ID: 30644830
[TBL] [Abstract][Full Text] [Related]
9. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Medication-Related Osteonecrosis of the Jaw: Controversies in Causality and Therapy.
Halpern LR; Adams DR
Dent Clin North Am; 2024 Jan; 68(1):67-85. PubMed ID: 37951638
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial peptide gene expression in medication-related osteonecrosis of the jaw.
Thiel Y; Ghayor C; Lindhorst D; Essig H; Weber F; Rücker M; Schumann P
Pathol Res Pract; 2020 Dec; 216(12):153245. PubMed ID: 33065485
[TBL] [Abstract][Full Text] [Related]
12. Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases.
Yuan A; Munz A; Reinert S; Hoefert S
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Feb; 129(2):133-140. PubMed ID: 31606424
[TBL] [Abstract][Full Text] [Related]
13. Computed tomographic assessment of early changes of the mandible in bisphosphonate-treated patients.
Taniguchi T; Ariji Y; Nozawa M; Naitoh M; Kuroiwa Y; Kurita K; Ariji E
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Sep; 122(3):362-72. PubMed ID: 27544397
[TBL] [Abstract][Full Text] [Related]
14. Management of Medication-Related Osteonecrosis of the Jaw.
Williams WB; O'Ryan F
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):517-25. PubMed ID: 26515735
[TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
16. Update MRONJ and perspectives of its treatment.
Voss PJ; Poxleitner P; Schmelzeisen R; Stricker A; Semper-Hogg W
J Stomatol Oral Maxillofac Surg; 2017 Sep; 118(4):232-235. PubMed ID: 28697987
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
[TBL] [Abstract][Full Text] [Related]
18. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
Fusco V; Campisi G; Bedogni A
Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
[TBL] [Abstract][Full Text] [Related]
19. Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab.
Yarom N; Lazarovici TS; Whitefield S; Weissman T; Wasserzug O; Yahalom R
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jan; 125(1):27-30. PubMed ID: 29102242
[TBL] [Abstract][Full Text] [Related]
20. Etiopathogenesis of medication-related osteonecrosis of the jaws: a review.
Bassan Marinho Maciel G; Marinho Maciel R; Linhares Ferrazzo K; Cademartori Danesi C
J Mol Med (Berl); 2024 Mar; 102(3):353-364. PubMed ID: 38302741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
